Revive Therapeutics Ltd. · CSE:RVV
Revive Therapeutics — Investor Presentation (April 2022)
17 slides from Revive Therapeutics's investor presentation, April 2022
Slide 1: A Specialty Life Sciences Company
A SPECIALTY LIFE SCIENCES COMPANY Corporate Presentation April 2022 OTCQB: FRANKFURT: RVVTF 31R Revive Therapeutics Ltd. | Office: 1-888-901-0036 | E-mail: mfrank@revivethera.com
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS Certain statements contained in this presentation constitute forward-looking information within the meaning of securities laws. Forward- looking information may relate to our future outlook and anticipated events or results and may include statements regarding our future f
Slide 3: Revive Therapeutics
REVIVE THERAPEUTICS Bucillamine Specialty life sciences company FDA approved Phase 3 clinical Developing novel Psilocybin focused on repurposing drugs trial for Bucillamine in the and Cannabidiol therapeutics Psilocybin for rare disorders and treatment of COVID-19 for various CNS and infectious dise
Slide 4: Pharmaceutical Strategy
PHARMACEUTICAL STRATEGY Clinical development of Targeting Rare Novel Uses, Targeting FDA Psilocybin, Disorders and Formulations, and Designations: Cannabidiol and Infectious Diseases, Delivery System Orphan, Fast track, Bucillamine Neurological Disorders, Breakthrough Mental Health and therapy Liver
Slide 5: Patent Portfolio
PATENT PORTFOLIO Title USPTO No. Status Use of Bucillamine in the Treatment of Infectious Diseases, including COVID-19 62/991,996 Non-Provisional patent filed Use of Bucillamine in the Treatment of Gout US9662305 Issued on May 30, 2017 US 8642088 Issued on February 4, 2014 Drug Delivery System US 95
Slide 6: Product Pipeline
PRODUCT PIPELINE Focus on Infectious Diseases, Psychedelics and Rare Disorders Stage of Product Indication Regulatory Status Development Infectious Diseases Phase 3 FDA approved Bucillamine COVID-19 (COVID-19) for Phase 3 Substance Use CTA with University of Psilocybin Disorder Phase 2 Wisconsin Met
Slide 7: Infectious Disease Opportunity
INFECTIOUS DISEASE OPPORTUNITY Received FDA approval for Focus on Bucillamine in Revive’s clinical history Bucillamine scientific FDA Phase 3 clinical trial the treatment of with Bucillamine rationale as an intervention for COVID-19 infectious diseases for COVID-19 (see Appendix) • Phase 3 study is
Slide 8: Psychedelics Opportunity
PSYCHEDELICS OPPORTUNITY Acquired Psilocin Pharma Corp. • Derrick Welch, Founder with 14 years of HC experience; 5 years in Cannabis • Worked with Xanthic Bio Pharma and Green Growth Brands • Developed water Soluble THC and CBD products (Beverages, effervescent tablets) Acquired Psilocybin Program f
Slide 9: Formulation & Delivery Technology
FORMULATION & DELIVERY TECHNOLOGY Delivering naturally extracted and synthetic psychedelics and cannabinoids DELIVERY SYSTEM Combines Tannin (antibacterial, antifungal, antioxidant, wound healing) and Chitosan (blood-clotting and antimicrobial) composites Releases (rapid, controlled, sustained), imp
Slide 10: Strategic Partners
STRATEGIC PARTNERS Psilocybin Oral Thin Infectious Diseases COVID-19 Clinical Sites Film Delivery Psilocybin Collaboration CRO Turkey Collaboration License of cannabidiol for treatment Psilocybin Biosynthesis R&D partnership of Autoimmune Hepatitis Collaboration Psychedelic pharma © COPYRIGHT 2020.
Slide 11: Expected Milestones
EXPECTED MILESTONES Q2 2022 • Complete Enrollment of Phase 3 study of Bucillamine in • FDA pre-IND meeting for Psilocybin oral thin film the treatment of COVID-19 • Apply for FDA EUA for Bucillamine in the treatment of • Scale up of Psilocybin oral thin film for FDA IND COVID-19 • Phase 2 study for
Slide 12: Peer Comparison - COVID (Market Caps)
PEER COMPARISON - COVID (MARKET CAPS) $790M Market Caps $750M in $ CAD $375M $60M © COPYRIGHT 2020. Revive Therapeutics Ltd. ALL RIGHTS RESERVED. 12
Slide 13: Peer Comparison - Psychedelics (Market Caps)
PEER COMPARISON - PSYCHEDELICS (MARKET CAPS) $1.02B $675M $580M $170M $60M Market Caps Fully-diluted and in $ CA D © COPYRIGHT 2020. Revive Therapeutics Ltd. ALL RIGHTS RESERVED. 13
Slide 14: Team
TEAM Management Clinical & Regulatory Board of Directors • Michael Frank • Dr. Kelly McKee, Jr., MD, MPH • Michael Frank Chairman and CEO Chief Scientific Officer, Consultant Chairman and CEO • Carmelo Marrelli • Dr. Onesmo Mpanju, PhD • William Jackson Chief Financial Officer FDA Regulatory Affairs
Slide 15: Stock Information
STOCK INFORMATION Ticker 52-Week High/Low Market Cap R V V (CSE) | R V V T F (OTCQB) | 31R (Frankfurt) CAD $0.65 / $0.175 CAD ~ $60,000,000 Share Price Capital Structure CAD $0.185 (March 31, 2022) 318,458,751 common shares © COPYRIGHT 2020. Revive Therapeutics Ltd. ALL RIGHTS RESERVED. 15
Slide 16: Appendix – Bucillamine Scientific Rationale for COVID-19
APPENDIX – BUCILLAMINE SCIENTIFIC RATIONALE FOR COVID-19 Current antiviral interventions for influenza have exhibited modest efficacy, especially in improving mortality in at-risk populations, such as the elderly.1,2 Novel antivirals have been plagued by poor oral bioavailability and lack of efficac
Slide 17: Appendix – Bucillamine Scientific Rationale for COVID-19 (References)
APPENDIX – BUCILLAMINE SCIENTIFIC RATIONALE FOR COVID-19 References 1. Muthuri SG, Venkatesan S, Myles PR et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data
Revive Therapeutics — Investor Presentation (April 2022) on 6ix